Peer-reviewed veterinary case report
Rabacfosadine chemotherapy improves lymphoma treatment in dogs
By Weishaar, Kristen M et al.·Published in Journal of veterinary internal medicine·2022·Colorado State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.
- Species:
- dog
Plain-English summary
A group of 158 dogs with lymphoma, a type of cancer affecting the lymph nodes, were treated with a new chemotherapy drug called rabacfosadine (RAB) to see how well it worked compared to a placebo. Dogs receiving RAB had a much longer time without disease progression—about 82 days compared to just 21 days for those on placebo. Additionally, 73% of the dogs treated with RAB showed a positive response, with some achieving complete remission. While some dogs experienced mild side effects like diarrhea, decreased appetite, and vomiting, these were generally manageable. Overall, RAB proved to be an effective treatment option for dogs with lymphoma.
People also search for: dog lymphoma treatment · rabacfosadine for dogs · dog cancer chemotherapy side effects
Abstract
BACKGROUND: Rabacfosadine (RAB, Tanovea-CA1) is a novel chemotherapy agent conditionally approved for the treatment of lymphoma in dogs. HYPOTHESIS/OBJECTIVES: To determine the efficacy and safety of RAB in dogs with lymphoma. ANIMALS: One hundred and fifty-eight client-owned dogs with naïve or relapsed multicentric lymphoma were prospectively enrolled from January to October 2019. METHODS: Dogs were randomized to receive RAB or placebo at a 3 : 1 ratio. Treatment was given every 21 days for up to 5 treatments. Study endpoints included progression-free survival (PFS), overall response rate (ORR) at a given visit, best overall response rate (BORR), and percent progression free 1 month after treatment completion. Safety data were also collected. RESULTS: The median PFS was significantly longer in the RAB group compared to placebo (82 vs 21 days; P < .0001, HR 6.265 [95% CI 3.947-9.945]). The BORR for RAB-treated dogs was 73.2% (50.9% complete response [CR], 22.3% partial response [PR]) and 5.6% (0% CR, 5.6% PR) for placebo-treated dogs (P < .0001). One month after the last treatment, 37 RAB-treated dogs (33%) were progression free compared with no placebo-treated dogs (P < .0001). The most common adverse events observed in the RAB group were diarrhea (87.5%), decreased appetite (68.3%), and vomiting (68.3%) and were generally low grade and reversible. Serious adverse events were reported in 24 RAB-treated (20%) and 5 placebo-treated dogs (13%). CONCLUSIONS AND CLINICAL IMPORTANCE: Rabacfosadine demonstrated statistically significant antitumor efficacy in dogs with lymphoma when administered every 21 days for up to 5 treatments as compared to placebo.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34952995/